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Contrast echocardiography is widely used in cardiology. It is applied to improve image quality, reader confidence and reproducibility both for
assessing left ventricular (LV) structure and function at rest and for assessing global and regional function in stress echocardiography. The use
of contrast in echocardiography has now extended beyond cardiac structure and function assessment to evaluation of perfusion both of the
myocardium and of the intracardiac structures. Safety of contrast agents have now been addressed in large patient population and these studies
clearly established its excellent safety profile. This document, based on clinical trials, randomized and multicentre studies and published clinical
experience, has established clear recommendations for the use of contrast in various clinical conditions with evidence-based protocols.
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Introduction
Contrast echocardiography is now an established technique in clinical
cardiology. Contrast echocardiography is performed for the assessment
of regional and global left ventricular (LV) function both at rest and
under stress for the optimal evaluation of LV structure and for the
assessment of myocardial perfusion. However, despite its availability,
the clinical use of contrast in rest echocardiography remains low. In
stress echocardiography (SE), the uptake is higher than in rest echocar-
diography, but it is not optimally utilized in parts of Europe and in the
USA. The use of myocardial perfusion remains very low. Although
safety issues of contrast have been addressed, lingering concerns
remained. However, over the last 5 years, new data have emerged in
contrast echocardiography and contrast protocols have become more
established. Furthermore, usefulness of contrast echocardiography has
been demonstrated in clinical conditions not recommended before.
In addition, more data on safety in large study population have
now emerged. Thus, strong data supporting use in previously indicated
clinical conditions and newer indications has prompted this recommen-
dation paper. We have classified the level of recommendation as Class
1 (evidence and/or general agreement that a given procedure is benefi-
cial and effective), Class II (conflicting evidence and or divergence of
opinion about the usefulness/efficacy of procedure, Class IIa (weight of
evidence is in favour of its usefulness/efficacy), Class IIb (weight of evi-
dence is less well established regarding efficacy) and Class III (evidence
or general agreement that the given treatment or procedure is not use-
ful/effective. We have classified the strength of recommendation as
Level A (based on multiple randomized studies or meta-analysis), Level
B (single randomized study or multicentre trials or large trials) and
Level C (expert opinion, small registry studies and small clinical trials).
Contrast agents
Present-generation contrast agents are microbubbles approximately the
size of a red blood cell (<7lm in diameter) consisting of a shell and
encapsulated gas. The echogenicity and ultrasound properties of the
contrast agents are determined by the size, shell and encapsulated gas of
the microbubbles within the various contrast agents. Microbubble ultra-
sound scattering is proportional to the sixth power of the radius, so the
largest bubble capable of passing through the pulmonary microcircula-
tion will have the best backscatter properties.1–4 However, the signals
obtained from ultrasound contrast agents are not only due to scattering.
The harmonic properties of microbubbles are a function of their
non-linear oscillation, which means that they reflect sound not only
at the fundamental frequency of the ultrasound source but also at
higher harmonics.5 The microbubbles must be stable enough to resist
destruction at normal ultrasound power outputs and so maintain a
sufficient concentration in the heart to give a satisfactory image. This
is largely a factor of solubility of the gas in blood, with high-
molecular-weight bubbles being less soluble and less diffusible and
therefore more stable.5 Lipid or albumin shells have been used to
reduce outward gas diffusion. Characteristics of the three commer-
cially available contrast agents are listed in Table 1.
Recommendations
All commercially available contrast agents are suitable for assessment
of LV function, structural LV abnormalities and myocardial perfusion
(Class I, Level B).
Contrast imaging modalities
Contrast imaging utilizes the non-linear scattering properties of ultra-
sound contrast agents to facilitate their detection within the heart.6–8
The microbubbles oscillate within the ultrasound beam and the
.................................................................................................
Table 1 Current commercially available ultrasound
contrast agents
Agent Manufacturer Shell Gas
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degree of oscillation, in part depends upon the intensity of the inci-
dent ultrasound. The measure for intensity of the transmitted ultra-
sound is the mechanical index (MI), which is the peak negative
pressure of the ultrasound wave divided by the square root of centre
frequency and is >0.8 for most non-contrast imaging. At higher ultra-
sound intensities (MI > 0.5) microbubble destruction can occur, and
when the gas is released from the bubbles, a strong acoustic signal
is produced, which can be detected by the ultrasound system.
However, contrast microbubble destruction makes high MI imaging
modalities unsuitable for real-time contrast imaging.9,10
To use real-time imaging of contrast within the LV cavity and/or
myocardium, it is necessary to reduce significantly the transmitted
ultrasound power (intermediate or low MI imaging), and this has
required more sophisticated, contrast-specific imaging modalities.11
These modalities have unique features and have been named according
to the developing ultrasound system manufacturer: power pulse inver-
sion, power modulation and cadence (or coherent) contrast imaging
(Figure 1). All these types of modalities rely on the fact that tissue is
essentially a linear and relatively predictable ultrasound scatterer, espe-
cially at low ultrasound energy levels, whereas contrast microbubbles
are not and are therefore described as being ‘non-linear’. When using
this kind of imaging modality, the image will normally be totally dark
prior to contrast administration, confirming effective suppression of tis-
sue data. This type of imaging is very effective for LV endocardial bor-
der enhancement, as it demonstrates a sharp demarcation between
the contrast-enhanced cavity and the myocardium. With minor modifi-
cation and increased contrast concentration, it can also effectively
detect and display contrast within the myocardium, facilitating the eval-
uation of myocardial perfusion as described later.11 It is common to
combine this form of low MI contrast imaging with a burst of a few
frames of high MI imaging (Flash) to destroy contrast within the myo-
cardium. This allows the qualitative and quantitative assessment of con-
trast replenishment into the myocardium and is also discussed later.
Harmonic imaging has become the standard imaging technique for
native (tissue) echocardiography, although it was originally developed
to enhance the detection of contrast agents (Table 2). To use it opti-
mally for contrast studies, the transmit power must be reduced from
an MI of 1.0 to 0.2–0.5. However, even this power level is still rela-
tively high and can cause destruction of the contrast in the near field
of the transducer as well as create confounding tissue signals in the
myocardium, which impairs the delineation of the endocardium and
therefore MI may be reduced to <0.2.
Intermediate and low MI imaging
For clinical studies, the newer contrast-specific imaging modalities
(Pulse inversion, Power Modulation and Cadence Pulse Sequencing)
provide the best LV opacification (LVO) (homogeneous contrast and
excellent endocardial border definition).12 Contrast-specific imaging
modalities apply a lower transmit power (MI < 0.5) compared with
the power transmitted in non-contrast echocardiography (MI > 0.8).
In commercially available echocardiography scanners, there is often
an option between intermediate MI (<0.5) and low MI (<0.2) settings.
The latter have been used for myocardial perfusion imaging.
However, the low MI contrast-specific settings are also recom-
mended for assessment of LV function.
Because of the low transmit power, less contrast is destroyed and,
therefore, less contrast is required compared with the high MI methods
for optimal imaging. In addition, myocardial opacification, which allows
assessment of perfusion, can be assessed simultaneously. Thus, perfusion
can be assessed without prolongation of the LV contrast opacification
(LVO) contrast study and without increasing the amount of contrast
agent infused. Scanning with the new low-power contrast-specific imag-
ing modalities for the detection of myocardial perfusion is an ‘off-label’
application, as none of the currently available contrast agents have been
approved for this indication. It should be noted, however, that because
the real-time low MI modes transmit multiple pulses down each image
scan line, relatively low frame rates may result in older systems, which
are not optimal for wall motion assessment. This may be usually over-
come by narrowing the sector width until the frame rate is at least
25 Hz that is preferable for optimal wall motion assessment during SE.
Low MI contrast-specific techniques display the contrast within
the cavities of the heart, and because contrast microbubbles are red
blood cell tracers, they accurately display the myocardial blood
within the intra-myocardial vessels. The blood volume within the
myocardial vessels comprises only 12% of the myocardium.
Therefore, the myocardial opacification is always much less intense
than the cavity opacification, providing an excellent differentiation
between the two for endocardial delineation. The myocardial con-
trast is also very useful for assessing thickening of the myocardium—
reduction of wall thickening is the hallmark for myocardial ischae-
mia—and myocardial perfusion. However, for the assessment of LV
structure, particularly non-compaction or very small thrombi very
low MI may miss these abnormalities. This is because of the limited
spatial resolution these structures will not reflect harmonic signals at
this low MI and delineation with contrast will be difficult. On the
other hand, with intermediate MI imaging, harmonic signals from
these structures will help to delineate these pathologies better. Low
MI imaging modalities are also available for transoesophageal echo-
cardiography (TOE) on some scanners, where they could be used for
assessment of LAA thrombi (see Left atrial appendage visualization
with contrast agent use during TOE section).
Recommendations
Contrast-specific imaging modalities should be used (Class I, Level B).
The low MI methods are particularly useful, as they provide simulta-
neous assessment of wall motion and myocardial perfusion and
require less contrast agent compared with methods using higher MI
(Class I, Level B). For the optimal assessment of LV structure, switch-
ing to intermediate MI imaging is preferable (Class IIa, Level B).
Contrast administration
Infusion method
Infusion of contrast agent has been used in multiple studies using SE—
in particular when myocardial perfusion was assessed in addition to LV
wall motion (see Myocardial contrast echocardiography section).
Continuous infusion of ultrasound contrast agents usually requires an
infusion pump, although it is also possible to do this using a modified
gravity fed intravenously (IV) for LuminityVR /OptisonVR . However, inter-
mittent agitation of the contrast is required to maintain the homogene-
ity of distribution of the microbubbles, because they rise quickly within
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Figure 1 Contrast-specific imaging using power modulation (A) and pulse inversion (B): multiple pulses are transmitted down each scan line.
Alternate pulses are 180 out of phase with other or vary in magnitude of amplitude by a fixed ratio or are a combination of both strategies. When
alternate backscattered signals are received, which are perfectly out of phase or proportionally altered in amplitude, they are processed by the imag-
ing software as being derived from tissue and therefore are filtered out and suppressed. All remaining ‘non-linear’ signals are considered to be derived
from contrast microbubbles and are displayed. (Senior et al EACVI Echo Tool Box)
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..the solution. Agitation can be performed manually by slowly rocking
the syringe or the bag to and fro. A special infusion pump has been
developed for SonoVueVR , which provides constant agitation. The
pump can be prepared in a few minutes prior to the study while the
patient is being prepared or during the baseline echo examination. By
an alternating rotating action, the contrast agent is agitated preventing
bubbles separating and floating to the surface. The pump is then kept in
a standby mode. The pump is started by the echocardiographer using a
remote control and no additional staff is needed. Although the pump
provides the possibility of an initial small bolus, a constant infusion of
SonovueVR 0.8 mL/min from the start is usually satisfactory and need
not be changed in the majority of patients. In contrast to a bolus injec-
tion, a continuous infusion over a short time provides stable conditions
to acquire loops from different scan planes and provides a steady-state
level to quantitatively assess myocardial perfusion. During SE, the infu-
sion can be stopped at any time and resumed when needed. Between
infusion periods, the contrast agent is automatically agitated. During
dobutamine stress echocardiography (DSE), the contrast infusion
should be connected through a three-way tap or a small bore Y con-
nector at the IV cannula, permitting simultaneous dobutamine infusion.
Bolus injection
It is also possible to use slow bolus injections of all agents (SonovueVR
0.5 mL, LuminityVR 0.2 mL and OptisonVR 0.2 mL), followed by slow
5 mL saline flush over 20 s. However, bolus administration is not as
controlled or reproducible as infusion to provide a steady and uni-
form opacification of the LV cavity and or the myocardium. Bolus
injection has been used in most of the published studies for the
assessment of LV structure and function.
Recommendations
Bolus injections of the contrast agent are adequate for the assess-
ment of LV function and diagnosis of structural LV abnormalities such
as apical hypertrophy, aneurysms, cardiomyopathies and thrombi
(Class I, Level A). Infusion of contrast is optimum for the assessment
of myocardial perfusion and for perfusion assessment of cardiac
masses (Class I, Level A).
For infusion of the ultrasound contrast agents, a special pump that
agitates the contrast agent is preferable (Class IIa, Level B).
Simultaneous infusion of ultrasound contrast agents with dobut-
amine or adenosine can be performed through the same IV cannula
(Class I, Level B).
Efficacy of contrast agents in
echocardiography
Enhancement of LV endocardial border
There is a large body of evidence for the use of contrast agents in
enhancing endocardial LV borders. The application of ultrasound
contrast agents leads to an improved delineation of endocardial LV
borders (Figure 2). All the three currently approved ultrasound
contrast agents have been evaluated in larger multicentre trials
required by European Medicines Agency (EMA) and Food and Drug
Administration (FDA) for approval.13–15
In addition to the multicentre studies for approval, further single-
centre studies were performed and demonstrated the ability of
contrast echocardiography in improving endocardial definition
(Table 3).16–31 Three studies have demonstrated the utility of contrast
enhancement in patients on intensive care units.27–29 The earlier clinical
trials for approval have been performed using fundamental imaging.
The introduction of harmonic imaging for routine echocardiographic
imaging has resulted in a significant improvement of image quality.32,33
However, there is still a significant proportion of studies obtained with
harmonic imaging in which images are suboptimal, and these studies
benefit from the application of ultrasound contrast agents.34 But the
....................................................................................................................................................................................................................
Table 2 Contrast imaging modalities
Power (MI) Type of
Imaging
Technology Advantages Disadvantages
High (0.8–1.0) Intermittent • Power Doppler
(ultraharmonics)
• Very sensitive for detec-
tion of contrast
• Cannot assess wall motion
simultaneously







• Power pulse inversion
• Cadence pulse sequencing
• Coherent contrast imaging
• Wall motion can be
assessed in real time
• Destruction-replenish-
ment modes available
• Simultaneous assessment of perfu-
sion is limited
• Artefacts from bubble destruction
in the near field
• Less sensitive for contrast detec-





• Power pulse inversion
• Cadence pulse sequencing
• Coherent contrast imaging




• Limited spatial and temporal reso-
lution and dynamic range
aIn the ASE Sonographer Guidelines, intermediate MI corresponds to low MI and low MI to very low MI imaging.
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Figure 2 Apical four- and two-chamber views (top left and right) with poorly visualized borders between the compact and trabeculated myocar-
dium. The corresponding recording obtained after injection of contrast agent (0.5 mL SonoVueVC ) show adequate delineation of the LV cavity from
the myocardium (bottom left and right).
....................................................................................................................................................................................................................
Table 3 Efficacy of contrast agents on LV image enhancement
Patients (n) Comparator Contrast agent Type of improvement Author Year
175 Native echo Albunex Endocardial definition improved in 83% patients Crouse et al.16 1993
254 Albunex Echogen Echogen improved endocardial definition improved in
88% patients; Albunex improved endocardial defini-
tion improved in 45% patients
Grayburn et al.17 1998
203 Albunex Optison Optison increased visible endocardial border length by
7.6 ± 4.8 cm; Albunex increased visible endocardial
border length by 3.4 ± 4.6 cm
Cohen et al.18 1998
218 Native echo SonoVue Mean improvements in the endocardial border visualiza-
tion score 3.1–3.7
Senior et al.19 2000
211 Saline Definity Endocardial border visualized in 47% segments without
contrast and 81% after contrast
Kitzman et al.20 2000
70 Native echo Optison Harmonic imaging: uninterpretable wall motion in
4.4 segments/patient; Contrast echo: uninterpretable
wall motion in 1.1 segments/patient
Reilly et al.21 2000
50 Native echo Optison Conversion of non-diagnostic studies in 85% of patients
with contrast in 15% with tissue harmonic imaging
compared with fundamental imaging
Kornblut et al.22 2000
Continued
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number of suboptimal studies may vary depending on the mix of
patients—in particular on the number of patients scanned on intensive
care units. This was confirmed in a large study by Kurt et al.30 who pro-
spectively enrolled 632 patients with technically difficult echocardio-
graphic studies. After contrast echocardiography, the percentage of
uninterpretable studies decreased from 11.7% to 0.3% and technically
difficult studies decreased from 86.7% to 9.8% (P< 0.0001).
Quantitative assessment of LV volumes
and function
Volumetric measurements are usually based on tracings of the inter-
face between the compacted myocardium and the LV cavity accord-
ing to the recent American Society of Echocardiography (ASE)/
European Association of Cardiovascular Imaging (EACVI) recom-
mendations for cardiac chamber quantification by echocardiography
for adults.35 However, it can be difficult to differentiate the compact
myocardium from the trabeculated layer—in particular in the apical
LV segments. Therefore, quantitative assessment of LV volumes is
often not feasible using unenhanced echocardiography.36
The value of 2D contrast echocardiography for quantification of LV
volumes and ejection fraction (EF) was assessed in 17 studies including
2 multicentre studies using cardiac magnetic resonance (CMR), nuclear
imaging, electron beam computed tomography or TOE as a reference
(Table 4).37–54 No significant difference was found when EF was com-
pared between non-contrast 2D echocardiography, contrast 2D echo-
cardiography and the reference methods. The inter- and intra-
observer variability of EF measurements of contrast 2D echocardiogra-
phy was significantly better than that of non-contrast 2D echocardiog-
raphy and similar to CMR. Contrast 2D echocardiography is
particularly useful in patients who had two or more adjacent poorly
visualized segments, which represents the current licensing of the
contrast agents. However, a benefit of contrast echocardiography has
also been demonstrated in patients in whom image quality was visually
judged as adequate. In a study consisting of 110 patients, the accuracy
of intravenous contrast echocardiography was found to be significantly
better than unenhanced tissue harmonic imaging when compared with
cardiac magnetic resonance imaging irrespective of imaging quality.55
Larsson et al.56 performed contrast echocardiography in 192 patients
all with adequate acoustic windows and found better reproducibility
for assessment of EF compared with unenhanced echocardiography.56
The superior reproducibility of 2D contrast echocardiography com-
pared with non-contrast echocardiography becomes clinically relevant
when clinical management depends on accurate measurements of LV
volumes and EF rather than on a semi-quantitative classification. This is
the case in patients assessed for intracardiac defibrillator (ICD) or car-
diac resynchronization therapy (CRT) or when serial measurements of
EF are performed to monitor cardiotoxic effect of cancer drugs such
as trastuzumab. Contrast echocardiography has been recommended
in patients in whom assessment of EF is not feasible by non-contrast
3D echocardiography.57 Measurements of EF by 2D contrast echocar-
diography have been shown to be feasible and highly reproducible in a
large cohort of consecutive patients undergoing chemotherapy with
cardiotoxic drugs.58,59
During 3D echocardiography, it can be difficult to differentiate
between the compact myocardium and the trabeculae. (Figure 3).60 In
one multicentre study comparing non-contrast and contrast 3D echo-
cardiography with CMR and several single-centre studies (mostly
in comparison with CMR) improved inter-observer variability and
better accuracy of EF measurements was demonstrated.43–46,50,52–54
However, there was inconsistent superiority over 2D contrast echo-
cardiography. There were limitations of 3D contrast echocardiography
due to inhomogeneous LV contrast bubble destruction in the near
field, which resulted in increased inter-observer variability.43
....................................................................................................................................................................................................................
Table 3 Continued
Patients (n) Comparator Contrast agent Type of improvement Author Year
40 Native echo Optison Segmental score improved from 4.5 to 11.6 in ICU
patients with poor acoustic windows
Nguyen et al.23 2001
100 Native echo Levovist Conversion of non-diagnostic image from 33% to 77% Chen et al.24 2001
264 Albunex saline SonoVue Mean increases in LVEBD 3.8–18.2 for SonoVue, 0.1–4.3
for Albunex
Nanda et al.25 2002
409 Saline Imagent Agreement of segmental wall motion scores; improved
from 31% and 39% to 48% and 65%
Nanda et al.26 2003
92 Native echo Definity 51% studies salvaged with contrast Nash et al.27 2004
30 Native echo Sonicated albumin Salvage rate of 77% of non-diagnostic studies in venti-
lated patients
Costa et al.28 2005
62 Native echo Definity Optison conversion of non-diagnostic to diagnostic study from
11% to 81% when scans are performed by fellows
Makaryus et al.29 2005
632 Native echo Definity Technically difficult studies became contrast adequate
89.9%
Kurt et al.30 2009
100 Native echo SonoVue Inter-observer agreement for wall motion scoring con-
trast echo (88%, kappa 0.78) non-contrast (76%,
kappa 0.60)
Galema et al.31 2011
LVEBD, left ventricular endocardial definition (modified from Bhatia and Senior).
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Table 4 Efficacy of 2D and 3D contrast echocardiography for assessment of LV volumes, EF or regional wall motion
abnormalities—comparison with other imaging modalities
Patients (n) Comparator
agent
Contrast Agreement vs. comparator main findings 3D Author Year
40 CMR EchoGen EF: without contrast 0.85–0.93 contrast, P< 0.3 Hundley et al.37 1998
EDV without contrast 0.92–0.95 contrast, P< 0.02
ESV without contrast 0.94–0.97 contrast, P< 0.01
Correct classification of EF improved
From 71% before contrast to 94% after contrast
50 RNI Optison Linear correlation coefficient: Nahar et al.38 2000
0.84 (EF-non contrast) 0.96 (EF-contrast)
51 RNI Levovist 0.89 (EF non contrast) 0.97 (EF contrast) Yu39 2000
0.71 (EDV non contrast) 0.93 (EDV contrast)
0.89 (ESV non contrast) 0.97 (ESV contrast)
26 EBCT Optison EDV, ESV and EF: Thomson et al.40 2001
No significant difference between contrast echo and EBCT
32 TOE Optison 34% segments visualized with harmonic imaging Yong et al.41 2002
87% segments visualized with contrast echo
50% patients EF possible with harmonic imaging
97% patients EF possible with contrast echo
Linear correlation coefficient: 0.83 (EF non-contrast) 0.91
(EF contrast)
110 CMR Luminity Limits of agreement: Malm42 2004
SonoVue EF: -18.1% to 8.3% (non-contrast), 7.7% to 4.1%
(contrast)
EDV: -98.2 to - 11.7 mL (non-contrast) -59.0 to 10.7 mL (contrast)
ESV: -58.8 to 21.8 mL (non-contrast) -38.6 to 23.9 mL (contrast)
46 CMR Definity Patients with good acoustic windows, correlation with MRI: þ Caiani et al.43 2005
3D echo data sets obtained without contrast (EF, r= 0.86,
SEE = 8.8%)
compared with those obtained with contrast 3D (EF, r= 0.71,
SEE = 12.3%)
20 CMR Definity Triggered imaging (End diastole/end systole) increases accuracy of
3D contrast volume measurements
þ Caiani et al.44 2005
24 CMR Definity In 16 patients with poor endocardial definition correlation with
CMR was better on contrast 3D echo (r= 0.61) than on native
3D echo (r= 0.76)
þ
Corsi et al.45 2006
53 CMR SonoVue 95% limits of agreement for EF between echocardiography and MRI þ Malm et al.46 2006
2D non-contrast -12.5 to 6.7%, triplane non-contrast -17.2 to 9.9%
2D contrast -7.1 to 5.8%, triplane contrast -9.4 to 6.4%
36 CMR SonoVue EF classification agreement: 69% (non-contrast; kappa 0.33) and
83% (contrast; kappa 0.66)
Lim et al.47 2005
120 CMRa SonoVue RWMA inter-observer agreement CMR: kappa 0.43RWMA inter-
observer agreement non-contrast 2D echo: kappa 0.41RWMA
inter-observer agreement contrast 2D echo for: kappa 0.77EF
inter-observer reliability ICC 0.91 (contrast 2D), 0.86 (CMR),
0.79 (non-contrast 2D echo)
Hoffmann et al.48 2006
Hoffmann et al.49 2005
50 CMR Optison EF classification agreement with CMR þ Jenkins et al.50 2009
Definity non-contrast 2D echo: 68% agreement, kappa 0.45
contrast 2D echo: 62% agreement, kappa 0.20
non-contrast 3D echo 74% agreement, kappa 0.39
contrast 3D echo 80% agreement, kappa 0.56
contrast 3D superior to other techniques in patients with previous
infarction
Continued
1205g R. Senior et al.
Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/18/11/1205/4157368
by Université de Liège user












..In the 2015 ASE/EACVI recommendations for chamber quantifica-
tion, normal values for contrast echocardiography have not been
mentioned, as there have been no studies designed to address nor-
mal values in contrast echocardiography.35 Contrast echocardiogra-
phy and non-contrast echocardiography give similar LVEF values
compared with CMR. However, both end-diastolic and end-systolic
volumes are higher when measured using contrast echocardiography
compared with a non-contrast echocardiography for reasons stated
before. Thus, LV volumes values—based on non-contrast images—
recommended by EACVI/ASE cannot be used interchangeably unlike
LVEF with values obtained by contrast echocardiography.
Recommendations
(1) Contrast echocardiography should be used when two or






Contrast Agreement vs. comparator main findings 3D Author Year
150 CMR SonoVue mean EDV difference: MRI – non contrast 2D echo 54.9 mL Mistry et al.51 2010
MRI – contrast 2D echo 41.7 mL
41 CMR SonoVue contrast 3D echo superior to 2D and 3D non-contrast echo þ Saloux52 2014
for inter-observer variability and agreement with CMR
62 CMRa SonoVue RWMA: accuracy to detect expert panel defined þ Hoffmann et al.53 2014
84% (CMR), 78% (2D contrast echo)
76% (3D contrast echo)
EF: mean percentage of error þ Hoffmann et al.54 2014
CMR 7.9%, 2D echo 14.3%, 3D echo 13.6, 14.3%
contrast 2D echo 8.0%, contrast 3D echo 7.4, 8.5%
aMulticentre studies, studies including 3D echocardiography are highlighted with a þ.
RNI, radionuclide imaging; EBCT, electron beam computed tomography.
Figure 3 Orthogonal slices obtained from a full-volume data set recorded with 3D contrast echocardiography.
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(2) Contrast 2D echocardiography should be considered irrespective
of image quality when clinical management depends on accurate
measurements of LVEF such as monitoring of patients treated with
cardiotoxic drugs and when implantation of ICD or CRT devices
are considered (Class IIa, Level B).
(3) The normal values for EF and grading of reduced EF (mild, moderate
or severe) but not LV volumes published in the recent ASE/EACVI
recommendations can be used for contrast echocardiography
(Class IIb, Level B).
(4) Because of limited number of studies, 3D contrast echocardiogra-
phy is not yet recommended (Class III, Level B).
Assessment of regional LV function
There is also strong evidence that contrast agents improve the
assessment of regional LV wall motion in both 2D and 3D modes.
Analysis of regional LV wall motion abnormalities (RWMA) is sig-
nificantly limited by considerable inter-reader variability even
when using high-quality non-contrast 2D and 3D echocardio-
graphic recordings.48 Two multicentre studies involving a total of
180 patients addressed the inter-reader agreement of unen-
hanced and contrast-enhanced 2D echocardiography in compari-
son with CMR and ventriculography.48,53 One of these studies
also included comparisons of non-enhanced and contrast-
enhanced 3D echocardiography on 63 patients.53 For these stud-
ies, a standard of truth for the presence of RWMA was obtained
by an independent expert panel decision. In both multicentre
studies, contrast 2D echocardiography significantly reduced
inter-observer variability for the assessment of RWMA and
improved the accuracy to detect expert panel-defined RWMA. In
the first multicentre study, the accuracy to detect RWMA was
highest for contrast 2D echocardiography, followed by CMR,
unenhanced 2D echocardiography and cineventriculography.48 In
the second multicentre study, accuracy to diagnose RWMA was
highest for CMR (84%), followed by 2D contrast echocardiogra-
phy (78%) and 3D contrast echocardiography (76%).53 The use of
3D echocardiography required contrast application similar to 2D
echocardiography to reduce inter-observer variability on regional
LV function. With 3D echocardiography, the use of contrast
increased the inter-reader agreement between two blinded off-
site readers from 0.27 to 0.42 (kappa values).
In addition to the two multicentre studies, single-centre studies
confirmed the benefit of ultrasound contrast agents for the assess-
ment of regional systolic LV function.21,41,45,56 It has been shown that
contrast echocardiography improved confidence of the interpretation
of regional LV wall motion and increased the inter-observer agree-
ment from 80% (non-contrast tissue harmonic imaging) to 95% (2D
contrast echocardiography) in intensive care unit patients.21 In a fur-
ther evaluation of similar group of patients, comparing the results with
TOE, it was concluded that the use of intravenous contrast echocar-
diography significantly improved the feasibility and accuracy of esti-
mated LVEF over tissue harmonic imaging.41 Larsson et al.56
compared contrast echocardiography with non-contrast echocardiog-
raphy in 192 patients with good acoustic windows. They found an
increased reproducibility of wall motion score index using contrast
2D echocardiography and that 55% of the patients were reclassified
with motion abnormalities by contrast analysis. In patients 7–10 days
after acute MI assessment of LV ESV and EF by contrast
echocardiography showed incremental prognostic value for predicting
hard events beyond clinical and non-contrast determined LV
function.61
Recommendations
Contrast 2D echocardiography should be considered when two or
more contiguous LV segments are not adequately visualized on non-
contrast echocardiography and management of the patient will
depend on whether there are regional wall motion abnormalities or
not (Class I, Level A).
Except for SE (see below), there is not good evidence of using
contrast agents in patients with good acoustic windows (Class III,
Level B).
Assessment of LV structure and masses
Contrast opacification particularly facilitates the identification of api-
cal abnormalities.62 This is because native tissue harmonic echocar-
diography is unable to overcome the noise, clutter and reverberation
artefacts in the near field as tissue harmonic signals are weak at the
near field (Figure 4). Multiple reports are available for using contrast
echocardiography for establishing or excluding the presence of apical
hypertrophic cardiomyopathy63–66, non-compaction 67–69, divertic-
ula70 and life-threatening complications of MI, such as myocardial
rupture and LV pseudoaneurysm (Figure 5).71–76 The contrast echo-
cardiographic findings of apical hypertrophy and non-compaction
(prominent LV trabeculations and thinned compact myocardium)
are specific and usually need no further assessment with CMR. In sus-
pected myocardial rupture, contrast echocardiography is the only
bedside method to confirm or exclude myocardial rupture.
The utility of contrast agents to rule out or rule in LV thrombi has
been shown in larger cohorts when conventional echocardiography
was inconclusive (Figure 6).30,77–79 The obvious implications for man-
agement of the patients are further discussed in Clinical impact—
cost-effectiveness section. However, smaller mural and apical clots
may be missed despite contrast echocardiography.80,81 However,
prognostic implications for small mural thrombi post infarction is
uncertain. Cardiac thrombi may be indistinguishable from tumours,
especially when occurring adjacent to a normally contracting myocar-
dium. Presence of significant vascularization detected by contrast
echocardiography when using the perfusion protocol as described in
Myocardial contrast echocardiography section establishes cardiac
tumour.82 However, absence of perfusion does not confirm throm-
bus as avascular cardiac tumour is also common.
Recommendations
Contrast echocardiography should be considered when apical
hypertrophy and diverticula, pseudoaneurysm, myocardial rupture,
non-compaction and LV thrombi are suspected but not clearly docu-
mented or excluded on non-contrast images (Class I, Level B).
Contrast echocardiography for perfusion may be used in patients
with cardiac masses suspicious of a tumour to distinguish it from a
thrombus when CMR is not available or inconclusive (Class IIa, Level C).
Left atrial appendage visualization with
contrast agent use during TOE
TOE is established for the assessment of thrombi in the left atrium
and left atrial appendage (LAA).83,84 In the LAA, spontaneous echo
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contrast can impair visualization of thrombi and hypoechogenic
thrombi can be missed with standard TOE (Figure 7).85 A study
involving 41 patients with atrial fibrillation and dense spontaneous
echo contrast delineated contrast free masses characteristic of a clot
after injection of OptisonVR ,86 SonoVueVR was used in another study
involving 90 patients, and DefinityVR was administered in 100 patients
in a study at the Mayo Clinic.88 LAA thrombi could be definitely
excluded in more patients with contrast-enhanced TOE than with
unenhanced TOE (83.3% vs. 66.7%).88 Jung et al.87 followed their
patients after cardioversion; no embolic events were reported during
follow-up in patients with contrast-enhanced TOE. However, there
were 2 subsequent strokes in a control group of 90 patients in whom
only unenhanced TOE was performed prior to cardioversion. Similar
to the imaging of LV thrombi, contrast-specific imaging modalities
(e.g. contrast LVO using MI < 0.2) are suitable for TOE assessment of
LAA thrombi. However, contrast-specific imaging modalities are not
available on several TOE scanners, and then harmonic imaging with
an MI < 0.3 should be used.
Recommendation
Contrast injection may be considered when native images are incon-
clusive for the diagnosis of LAA thrombus (Class IIa, Level C).
Assessment of aortic disease
Contrast may have a role in the detection of aortic dissection.
Sensitivity and specificity of conventional transthoracic echocardiog-
raphy in the detection of aortic dissection increased after contrast
enhancement.89,90 Also using the transoesophageal approach, the
location of non-visualized entry tear, the correct identification of the
true lumen and the diagnosis of retrograde dissection increase after
contrast enhancement.89 Contrast echocardiography also helps to
confirm aortic pathology when images are suboptimal or suspicious
of being abnormal.91 Injection of contrast agent has been shown
improve display of clots in the aorta.92 In patients undergoing thora-
cic endovascular aortic repair procedures, contrast-enhanced TOE
has improved endoleak detection.93
Recommendations
In patients with acute aortic syndromes and in patients undergoing
thoracic endovascular aortic repair procedures, contrast agents may
be used to assess the aortic pathology if non-contrast 2D echocar-
diographic and Doppler images are suboptimal or ambiguous (Class
IIa, Level C).
Figure 5 Four-chamber view with incidental finding of a confined
echo-free area asterisk denotes adjacent to the LV apex (left).
Contrast echocardiography confirms a large false aneurysm, four-
chamber view, zoomed apex, and the red arrow shows the neck of
the aneurysm.75
Figure 4 Apical hypertrophy not well displayed on the four chamber view without contrast (left), after injection of ultrasound contrast agent it
was possible to measure the thickness of the apical myocardium.
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Detection of regional wall motion abnormality for the
diagnosis of coronary artery disease
Multiple studies have demonstrated the ability of ultrasound contrast
agents to improve visualization of regional wall motion abnormalities,
improve study quality, and increase reader confidence in study inter-
pretation (Table 5).94–112 Very low MI techniques add the possibility of
assessment of myocardial perfusion to the high quality assessment of
regional and global LV wall motion.12 Myocardial thickening abnormal-
ity during stress which is the hall-mark of myocardial ischemia is better
appreciated with myocardial opacification and subtle wall-thickening
abnormalities are better appreciated when concomitant sub-endocar-
dial perfusion defect is observed113 Six studies demonstrated better
agreement of coronary angiographic findings with contrast SE com-
pared with non-contrast studies and one study was compared with
fractional flow reserve.111 In a randomized crossover study by Plana
et al. patients underwent both non contrast and contrast enhanced
DSE.110 When compared with angiography the diagnostic accuracy for
the detection of coronary artery disease (CAD) in patients who
received contrast was significantly higher than with unenhanced SE for
the detection of CAD.110 A recent single-centre study demonstrated
the clinical value of 2D contrast echocardiography in 192 patients with
adequate image quality. Contrast echocardiography improved the
reproducibility of the wall motion score index and demonstrated
regional wall motion abnormalities in 55% of the patients who were
diagnosed as normal with non-contrast echocardiography.56
There is limited experience using 3D echocardiography with ultra-
sound contrast agents for SE.114–118 Despite the current limitations
of 3D contrast echocardiography at higher heart rate (need for
stitching data sets, lower temporal and spatial resolution when com-
pared with 2D contrast echocardiography), the available studies
demonstrated the feasibility of 3D contrast echocardiography. In one
of the largest clinical studies, sensitivity and specificity for detecting
wall motion abnormalities by 3D DSE was 58% and 75%, respectively,
when using 2D DSE results as the gold standard.115 However, the
total number of patients studied and is <200. There is the potential of
better results with the newer smaller probes and further advance-
ment of the 3D equipment.
Risk stratification/prognosis
The prognostic information from contrast-enhanced 2D SE
appears to be similar to that from non-contrast stress
Figure 6 Examples of LV thrombus (arrow) displayed after bolus injection of 0.1 mL LuminityVR (right), the corresponding plane (three-chamber
view) without contrast did not show the thrombus.
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.echocardiograms in patients with optimal image quality. This has
been demonstrated in patients with different reasons for poor
acoustic windows for example morbid obesity.109 A negative con-
trast stress echocardiogram has an excellent prognosis with an
annual event rate <1%.109 In a study involving 893 patients, the
3-year event-free survival rate was significantly lower in patients
with positive contrast dobutamine stress echo results than in
those with negative DSE results.119 In another study, performed in
consecutive patients presenting with suspected acute coronary
syndrome (ACS) but negative troponin and equivocal electrocar-
diography (ECG), SE provided diagnostic images in 99% of
patients, where contrast was used in over 60% of patients and
helped early discharge of patients with excellent outcome but
patients with an abnormal SE had worse prognosis.120
Limitations of contrast echocardiography
Adequate recordings for assessment of LV function and assess-
ment of LV structure can be achieved in the majority of patients.
However, the echocardiographers require training and under-
standing of the physics of microbubbles as well as the imaging
technology (see Training/accreditation requirements in contrast
echocardiography section). There are a few artefacts that are
unique for contrast echocardiography such as swirling (resulting
from bubble destruction or low dosages of contrast), blooming
(due to high-contrast dosage or inadequate gain setting) and
attenuation, where the contrast agent in the near field shadows
the deeper part of the left ventricle. These artefacts could be rec-
ognized and eliminated with simple measures (see Table 12). One
of the most frequent reasons for suboptimal recordings is acquisi-
tion of the images too early after bolus injections, when there is a
high concentration of microbubbles in the RV and LV cavity, which
can cause attenuation and/or blooming. It usually takes more than
20 s to get homogeneous contrast in the entire LV cavity. During
stress, this can be shorter. Finally, the microbubbles are very
....................................................................................................................................................................................................................
Table 5 Studies reporting benefit of using ultrasound contrast agents for stress echocardiography
Patients (n) Stress method Contrast agent Author Year
50 Dobutamine son.Albumin Porter et al.94 1994
30 Dobutamine Albunex Falcone et al.95 1995
16 Bicycle BY 963 Leischik et al.96 1997
30 Dobutamine Infoson Ikonomides et al.97 1998
36 Dobutamine BY 963 Schnaak et al.98 2000
200 Exercise/dobutamine Optison Malhotra et al.99 2000
29 Dobutamine Optison Vlassak et al.100 2002
38 Arbutamine SonoVue Brown et al.101 2004
283 Treadmill Optison Yokoyama et al.102 2004
117 Dobutamine Optison Dolan et al.103 2001
300 Dobutamine Optison Rainbird et al.104 2001
560 Not specified Definity Weiss et al.105 2005
40 Exercise SonoVue Rizzo et al.106 2005
62 Dobutamine SonoVue Hu et al.107 2007
135 Dipyridamole Definity Moir et al.108 2007
611 Dobutamine Definity/Optison Lerakis et al.109 2007
101 Dobutamine Definity Plana et al.110 2008
70 Dobutamine SonoVue Jung et al.111 2008
42 Dobutamine SonoVue Cosyns et al.112 2008
Only those studies are listed in which contrast agents were used to enhance endocardial visualization.
Figure 7 TOE recording of the left atrial appendage (LAA): on
the recording without contrast agent (left) spontaneous echo con-
trast (SEC) is displayed in the LAA but no thrombus can be
delineated. With contrast agent (right), two thrombi are delineated
as echo-free masses (white arrows) within the LAA. LA, left atrium;
LV left ventricle, Courtesy of Dr Andreas Helfen, St.-Marien-
Hospital Lu¨nen, Germany.
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.sensitive to pressure changes, e.g. applying negative pressure dur-
ing preparation by not following the instructions of manufacturers
or scanning with the ultrasound power, which is used for non-
contrast imaging, result in poor contrast images.
The additional cost may be a limitation—in particular in institutions
where patients have to pay for the contrast additionally. However,
alternative imaging methods for SE (e.g. nuclear imaging of CMR) are
more expensive, and there is good evidence that suboptimal record-
ings result in increased downstream costs (see Clinical impact—cost-
effectiveness section). This is also true for resting inconclusive or
inadequate studies without contrast.30
Recommendations
Stress echocardiography for the assessment of RWMA for the detec-
tion of myocardial ischaemia should be performed with contrast
agents when two or more contiguous segments are not adequately
visualized at rest (Class I, Level A) or during deep inspiration mimick-
ing cardiac motion during stress (Class IIa, Level C).225 In patients
with less than 2 segments not well-visualized contrast agents should
be given when myocardial perfusion is assessed in addition to LV wall
motion using low MI contrast imaging (see Myocardial contrast echo-
cardiography section).
Low MI contrast-specific imaging modalities should be used for SE
(see Contrast imaging modalities section), irrespective of whether
only wall motion or both wall motion and perfusion are assessed
(Class I, Level C).
There is not enough available data to recommend 3D contrast
echocardiography for stress testing (Class III, Level B).
Myocardial contrast echocardiography
Principles of myocardial contrast echocardiography
The volume of blood within the entire coronary circulation at rest in
diastole is approximately 12 mL/100g of left ventricular myocardium
and the predominant (90%) component of this resides within the
capillaries.121 The myocardial signal intensity emanating from the
contrast agent reflects the concentration of microbubbles within
the myocardium.122 When the myocardium is fully saturated during
a continuous infusion of microbubbles, the signal intensity reflects
relative capillary blood volume. Following clearance of microbub-
bles from the myocardium during brief burst of high-power imaging,
microbubble replenishment within the myocardium can be
observed (Figure 8).122 The capillary blood velocity is 1 mm/s with an
ultrasound beam elevation of 5 mm. Thus, it takes 5 s for complete
replenishment of the myocardium. Any decrease in myocardial
blood flow (MBF) prolongs replenishment time in proportion to the
Figure 8 Assessment of myocardial perfusion in the three-chamber view using the flash-replenishment method. Continuous infusion of 1mL DefinityVR /
min (1.3 mL diluted in 30mL saline) very low MI contrast-specific imaging (MI for imaging 0.09, for the flash 0.85). Before the flash (top right), the bright LV
cavity is well delineated from the myocardium and papillary muscle. During the flash the sector becomes bright (top mid) and in the first cardiac cycle after
the flash (top right), the contrast agent in the myocardium has disappeared. The still frames at the bottom are obtained at first (left), second (mid) and
fourth (right) cardiac cycle after the microbubbles have been cleared showing progressive replenishment within four cardiac cycles.
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reduction in MBF.123 Myocardial perfusion is tissue blood flow at the
capillary level. The two components of tissue blood flow are capil-
lary blood volume and red blood cell velocity. As the rheology of
microbubbles resemble red blood cell, the product of peak micro-
bubble intensity (relative myocardial blood volume) and their rate
of complete replenishment (representative of blood velocity) equals
MBF.
Detection and risk stratification of CAD
Following the clearance of microbubbles, in the normal myocardium
subtended by normal coronary artery, contrast appears within 5 s
(five cardiac cycles if the heart rate is 60 bpm) during replenishment
phase at rest; during stress, because MBF increases 4–5-fold nor-
mally (normal coronary flow reserve (CFR) is 4–5], replenishment
will be achieved by 1–2 s [2–3 cardiac cycles at a heart rate of 120
bpm). A delayed contrast appearance with reduced contrast inten-
sity in the subendocardium due to reduced blood flow velocity and
reduced capillary blood volume, respectively, is the hallmark of
flow-limiting CAD (Figure 9).122 An updated analysis showed that
the sensitivity and specificity of myocardial contrast echocardiogra-
phy (MCE) for the detection of CAD is 83% and 79%, respectively,
for vasodilator MCE (Table 6) and for dobutamine/exercise 88%
and 77%, respectively (Table 7). Single-photon emission computed
tomography (SPECT) is the most widely used myocardial perfusion
technique for the assessment of CAD. A meta-analysis of eight stud-
ies comparing the sensitivity and specificity of MCE with those of
SPECT/DSE for the detection of CAD showed that MCE was more
sensitive than SPECT for the detection of CAD.156 In an experimen-
tal study, it was shown that microbubble velocity is more sensitive
for the detection of stenosis severity than myocardial blood volume,
the latter is detected by SPECT, while MCE detects both.123 The lat-
ter property of MCE together with higher spatial resolution may be
responsible for the higher sensitivity of MCE compared with
SPECT. Subsequently, two large multicentre studies, where all
patients underwent coronary angiography, MCE and SPECT and
where all imaging modalities were read blindly in sites other than
the recruiting sites, showed that MCE demonstrated superior sensi-
tivity to SPECT.146,153 Both these trials also demonstrated high fea-
sibility of MCE performed in more than 50 centres across Europe
and the USA. Specificity of MCE was consistently lower than
SPECT. This was also shown in another multicentre study involving
CMR vs. SPECT, where CMR showed better sensitivity but specific-
ity was inferior.157 This was likely because of higher prevalence of
microvascular disease in this high-risk population, where all patients
underwent coronary arteriography. However, some perfusion
defects on MCE may be attributed to artefacts particularly in the
apex and the basal segments. These should be recognized and
should be corrected by appropriate manoeuvres described in
Training/accreditation requirement in contrast echocardiography
section of the article.
During demand, SE wall motion assessment remains the corner-
stone for the assessment of myocardial ischaemia. MCE, which
simultaneously assesses wall motion and perfusion, improves sen-
sitivity of SE by both improving the detection of wall thickening
abnormalities and the identification of perfusion defects.
Improved assessment in terms of both improved sensitivity and
the extent of ischaemia have been corroborated in several inde-
pendent studies.126,129,130,147,150,158 A large body of evidence now
exist (5679 patients) confirming the improved prognostic value of
perfusion when performed simultaneously during SE (Table 8).
This includes a large (over 2000 patients) randomized study,
which showed that perfusion assessment provided improved
prognostic information beyond wall motion assessment during
SE.160 A recent study also showed that when MCE was performed
routinely during SE in the day-to-day clinical service where MCE
was used in decision making provided improved prognostic out-
come over wall motion.159 The incremental prognostic value of
MCE in SE was demonstrated in a recent meta-analysis.172
Figure 9 Apical four-chamber view at rest (left) demonstrating normal myocardial perfusion at rest (5 s after myocardial contrast destruction).
Right, after stress, four-chamber view displayed 3 s after myocardial contrast destruction. Note sub-endocardial perfusion defect in the septum, apex
and transmural defect in the lateral wall. This suggests moderate LAD and severe LCx flow-limiting stenosis, which was confirmed by coronary
arteriography.134
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..However, it may be added that in most studies MCE was per-
formed in high-risk patients, where beneficial effect of MCE is
unequivocally noted. Thus, the benefit of MCE in low-risk patients
remains to be shown.
Detection of ACS
The diagnosis of ACS is based on the triad of clinical history, electro-
cardiography and cardiac markers of myocardial necrosis. The triad
could detect only 30% of patients with ACS.173 In a large multicentre
....................................................................................................................................................................................................................
Table 6 Myocardial contrast echocardiography with vasodilator stress in the assessment of coronary artery disease






Sensitivity Specificity Author Year
123 Adenosine 15 12 75 67 Heinle et al.125 2000
25 Dipyridamole 12 12 89 100 Rocchi et al.128 2003
85 Dipyridamole 70 43 91 70 Moir et al.131 2004




Peltier et al.132 2004
55 Dipyridamole 55 43 86 88 Senior et al.133 2004
52 Dipyridamole 52 22 82 97 Senior et al.134 2005
36 Adenosine 36 35 81 67 Winter et al.135 2004




Tsutsui et al.136 2005
123 Dipyridamole 123 96 84 56 Jeetley et al.137 2006
47 Adenosine 47 11 91 92 Karavidas et al.138 2006
120 Dipyridamole 89 62 83 72 Korosoglou et al.139 2006
70 Dipyridamole 40 25 84 93 Lin et al.140 2006
43 Dipyridamole 43 33 77 72 Malm et al.141 2006
55 Adenosine 50 32 88 89 Aggeli et al.142 2007
63 Dipyridamole 63 25 92 95 Hayat et al.145 2008
662 Dipyridamole 457 368 71 64 Senior et al.146 2009
400 Dipyridamole 116 71 97 74 Gaibazzi et al.147 2009
48 Adenosine 48 37 89 92 Vogel et al.148 2009
65 Adenosine 62 41 85 76 Arnold et al.149 2010
400 Dipyridamole 400 268 96 66 Gaibazzi et al.150 2010
150 Dipyridamole 150 102 96 69 Gaibazzi et al.151 2010
100 Regadenoson 98 52 80 74 Porter et al.152 2011
628 Dipyridamole 512 310 75 52 Senior et al.153 2013
150 Regadenoson 147 85 77 73 Abdelmoneim et al.155 2015
Mean (95% CI) 3571 2736 1820 83 (77–89) 79 (72–85)
....................................................................................................................................................................................................................
Table 7 Myocardial contrast echocardiography with dobutamine or exercise in the assessment of coronary artery
disease






Sensitivity Specificity Author Year
45 Dobutamine or exercise 45 32 87 66 Cwaig et al.124 2000
100 Exercise (treadmill or bike) 44 28 75 100 Shimoni et al.126 2001
44 Dobutamine 44 44 97 93 Olszowska et al.127 2003
140 Dobutamine 132 85 81 77 Chiou et al.129 2004
170 Dobutamine 170 127 91 51 Elhendy et al.130 2004
5250 Dobutamine 532 413 92 61 Aggeli et al.143 2008
42 Exercise (bike) 42 25 88 88 Miszalski-Jamka et al.144 2007




Miszalski-Jamka et al.154 2013
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study, MCE improved the detection of ACS beyond the triad of clini-
cal, ECG and biochemical markers at presentation and was equivalent
to SPECT for the prediction of outcome.174 However, the advan-
tages of MCE are that it allows both rapid assessment and simultane-
ous evaluation of wall motion and perfusion at the bedside. Reports
also suggest that MCE has higher sensitivity compared with standard
echocardiography and SPECT for the detection of ACS.175,176 In a
1000 patient study, resting perfusion and function with MCE was
shown to provide incremental prognostic information beyond clini-
cal, ECG and cardiac biomarker (troponin) parameters in patients
with suspected ACS.177 Normal function and perfusion at rest by
MCE demonstrated excellent outcome.178 In another study, stress
MCE with dipyridamole provided strong prognostic information in
patients with suspected ACS but normal 12-h troponin and non-
diagnostic ECG. A negative stress MCE predicted an excellent prog-
nosis.169 A larger study involving more than 500 patients in this popu-
lation confirmed excellent prognosis with no perfusion defect and
was superior to wall motion assessment alone.164
Detection of myocardial viability
Peak contrast intensity, a measure of capillary blood volume correlates
with microvascular density and capillary area, and is inversely related to
the collagen content.194 Animal studies have shown that MCE defect
size assessed 10–15 s after contrast administration, corresponded to
infarct size.179,180 This was confirmed in patients following acute MI
(AMI).181 The extent and intensity of contrast defect and the magni-
tude of resting MBF reduction predicted the transmural extent of myo-
cardial necrosis assessed by late gadolinium CMR imaging (Figure
10).182,183 The ability of MCE to predict functional recovery is compa-
rable to that of cardiac MRI (30 patients).182 Contractile response dur-
ing dobutamine infusion depends both on an intact microvascular
(important to sustain contractile proteins) and on MBF reserve. Thus,
DSE may be less sensitive than techniques that assess microvasculature
(MCE) for the detection of hibernating myocardium as MBF reserve
may be significantly reduced but the microvasculature may be intact.184
Therefore, MCE may be particularly useful in the evaluation of
myocardial viability in dobutamine non-responsive myocardium.185
Table 9 summarizes the accuracy of MCE for the prediction of myocar-
dial viability demonstrating a sensitivity of 85% and a specificity of 70%
for the prediction of recovery of function during follow-up. Studies
have also shown that among all the clinical, ECG and angiographic
parameters of reperfusion after AMI, contrast perfusion is the only
independent predictor of reperfusion.192,197,206 In two studies follow-
ing AMI, MCE provided incremental prognostic value over clinical and
LVEF data for the prediction of hard events207,208. In another study,
reversed LV remodelling following AMI predicted outcome and myo-
cardial reperfusion assessed by MCE was an independent predictor of
reversed LV remodelling.209 Finally, a recent meta-analysis in a patient
population with ischaemic cardiomyopathy, the sensitivity of MCE was
similar to that of metabolic markers of hibernating myocardium (Table
10).210 With accumulating evidence of its prognostic value for the
detection of myocardial viability over and above clinical markers and
LVEF, MCE is evolving as a useful bedside technique for the assessment
of myocardial viability.
Assessment of CFR by MCE
MBF using MCE can be assessed quantitatively.122 Assessment of
MBF during hyperaemia provided an accurate assessment of CFR,
which was subsequently replicated by other authors.211,132 MBF
assessed by MCE at rest and during hyperaemia closely correlated
with that assessed by positron emission tomography.212 Further
................................................................................................
Table 9 Myocardial contrast echocardiography in the
assessment of myocardial viability
Patients (n) Sensitivity Specificity Author Year
23 100 90 Agati et al.186 1997
34 77 83 Main et al.187 2001
46 69 85 Main et al.188 2002
35 94 87 Lepper et al.189 2002
19 68 88 Swinburn et al.190 2002
96 62 83 Senior et al.185 2003
35 80 67 Hillis et al.191 2003
15 88 74 Greaves et al.192 2003
50 92 75 Janardhanan et al.193 2003
18 90 63 Shimoni et al.194 2003
34 88 61 Aggeli et al.195 2003
33 86 44 Hillis et al.196 2003
30 96 18 Bolognese et al.197 2004
50 95 52 Sbano et al.198 2005
42 82 83 Janardhanan et al.182 2005
56 83 78 Hickman et al.199 2007
34 83 82 Huang et al.200 2005
31 98 32 Abe et al.201 2005
32 81 88 Korosoglou et al.202 2005
26 78 72 Tousek et al.203 2008
18 95 79 Shentu et al.204 2008
23 87 67 Hickman et al.184 2010
24 74 60 Fernandes et al.205 2011
Total: 804
Mean 85 70
Figure 10 Apical perfusion defect (no reflow) after stenting the
proximal LAD because of STEMI. The perfusion defect involves the
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..studies in various cardiovascular disease conditions showed that CFR
assessed by MCE can accurately assess both the presence and the
severity of flow-limiting CAD.132,134,213 This assessment can be per-
formed using both low- and high MI imaging techniques. With high
MI, the myocardium is first cleared of microbubbles and subsequent
replenishment is assessed in time either using intermittent high MI
imaging or by continous low MI imaging (Figure 11). Myocardial blood
flow is estimated by the product of peak contrast intensity (db) and
myocardial flow velocity (db/s) in each of the myocardial segments in
the apical views (preferably avoiding the basal segments—see below).
The MBF obtained in each segment can then be collapsed into the
three vascular territories. The process is repeated during stress myo-
cardial imaging. The ratio of the peak MBF and that of resting MBF
indicates CFR. The ratio of peak and resting myocardial blood veloc-
ity also provides a robust estimate of CFR.211.CFR assessed by MCE
predicted mortality in patients with heart failure beyond LVEF and
CAD.162 Recently, CFR assessed by MCE was shown to be reduced
in patients with hypoglycaemia, which may point towards mechanism
of high mortality in such patients.214
Assessment of CFR by contrast-enhanced coronary
Doppler imaging
In the European Association of Echocardiography SE expert consen-
sus statement of 2008, coronary Doppler imaging has been included
as to be added to vasodilator stress protocols. CFR on left anterior
descending coronary artery (LAD) territory adds prognostic value
when added to conventional wall motion analysis.215 For measure-
ment of the CFR, the LAD can be visualized using colour Doppler
along the anterior interventricular sulcus and the coronary flow can
be quantified by pulsed wave (PW) Doppler.216–218 The ratio of the
maximum velocity of diastolic mid-LAD flow during hyperaemia and
at rest is measured. Contrast agents have been shown to be useful to
enhance the PW Doppler signals of the LAD flow and facilitate PW
Doppler recordings of LAD flow.219 There is no evidence whether
the LAD CFR measured by PW Doppler provides incremental
information to myocardial perfusion imaging. However, the addition
of either CFR–LAD or myocardial perfusion assessment to standard
wall motion analysis and clinical parameters improved the prediction
of cardiac events.220
Limitations of MCE
MCE is the result of interaction between the microbubbles and
ultrasound power. Thus, variation in microbubble concentration
with each administration may influence the contrast intensity.
Lack of uniformity of ultrasound power in the ultrasound field
affects the estimation of myocardial blood volume and velocity.
Contrast intensity may be reduced at the bases of the heart,
because the ultrasound power is weakest in the far field, thereby
giving rise to false perfusion defects. Conversely, in the near-field,
destruction of contrast may result in false perfusion defects as the
ultrasound power is strongest here as it is nearest the transducer.
Furthermore, assessing myocardial viability in very thin myocar-
dium may be problematic because of frequent blooming artefacts
from the cavity. However, recent advancements in technology
and understanding of microbubble and ultrasound interaction and
thus recognition of artefacts and techniques to overcome these
artefacts has improved interpretation significantly. In a recently
concluded multicentre trials involving 50 centres in the USA and
Europe, diagnostic images could be obtained in 94–99% of
patients. The reproducibility of multiple MCE readers was non-
inferior and similar to that of SPECT readers.146,153
Recommendations
In SE laboratories with the availability of low MI imaging and expertise
of the staff, MCE should be considered in all patients undergoing
dobutamine, vasodilator SE and high-risk patients undergoing physio-
logical stress for improved diagnosis and risk stratification of CAD
beyond wall motion assessment (Class I, Level A). MCE may also be
performed to improve detection of myocardial viability particularly in
dobutamine non-responsive segments, where wall thickness is
....................................................................................................................................................................................................................
Table 10 Comparison of various Imaging techniques for the detection of hibernating myocardium
Technique No. of studies No. of patients Mean EF (%) Sensitivity (%) Specificity (%)
Dobutamine echocardiography–total 41 1421 25–48 80 78
Low-dose DbE 33 1121 25–48 79 78
High-dose DbE 8 290 29–38 83 79
Myocardial contrast echocardiography–total 10 268 29–38 87 50
Thallium scintrigraphy–total 40 1119 23–45 87 54
Tl-201 rest-redistribution 28 776 23–45 87 56
Tl-201 re-injection 12 343 31–49 87 50
Technetium scintrigraphy–total 25 721 23–54 83 65
Without nitrates protocol 17 516 23–52 83 57
With nitrates protocol 8 205 35–54 81 69
Positron emission tomography–total 24 756 23–53 92 63
Cardiovascular magnetic resonance–total 14 450 24–53 80 70
Low-dose dobutamine protocol 9 272 24–53 74 82
Late galdolinium-enhancement protocol 5 178 32–52 84 63
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.preserved (Class IIa, Level B). The flash-replenishment technique




Kurt et al.30 showed a significant impact of contrast echocardiography
on subsequent management of patients with suboptimal echocardio-
grams: in one-third of patients, diagnostic procedures were avoided
and drug management was altered in 10% with cost saving of $122
per patient. In patients assessed for the presence of clots, Siebelink
et al.79 reported that oral anticoagulants were started in 68% of the
patients with suspected thrombus and unnecessary anticoagulation
was avoided in 39%. In technically very difficult patients in the inten-
sive care, echocardiography cost savings of 17% were reported.41
Several studies demonstrated cost-effectiveness of using contrast
agents for SE: In patients with morbid obesity, non-diagnostic studies
were converted to diagnostic images in over 80% of patients with
detection of obstructive CAD in approximately 90% of patients with a
positive test.221 An open-label, randomized Phase IV multicentre study
evaluated the use of LuminityVC for the detection of CAD in 560
patients in whom non-contrast rest echocardiography had given
difficult-to-interpret images. Three months after the imaging, 36% of
patients with unenhanced imaging had required further diagnostic test-
ing compared with only 17% of those with enhanced images.105 Stress
ECG remains the test of choice in patients who can exercise with no
resting ECG changes with no previous history of CAD [American
College of Cardiology (ACC)/ American Heart Association (AHA)
guidelines and European Society of Cardiology (ESC) guide-
lines)].222,223 However, in several studies, SE using contrast agents was
significantly better than Ex-ECG for risk-stratifying patients to low-,
intermediate- and high-risk groups. Non-diagnostic tests were less fre-
quent, resulting in fewer referrals for other tests compared with stress
ECG and these translated to superior cost efficacy of SE compared
with Ex-ECG.224–227 The use of contrast in all patients undergoing SE
seems to be not cost-effective, if contrast agents are used for the
assessment of LV wall motion only.108A recent current opinion paper
by some authors of the ESC guidelines for stable angina concluded
from the evidence provided as above that SE should be the initial test
of choice in patients presenting with suspected stable angina.228
Figure 11 Demonstrating flash-replenishment images describing quantification of myocardial blood flow at rest and during stress and calculation
of myocardial blood flow reserve in the septum.
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Clinical safety of contrast agents
in echocardiography
Over 10 years of use of contrast on millions of patients established
the safety of contrast. In a large retrospective analysis of 18 000
patients, of which one-third received contrast agent in the acute set-
ting, there was no significant difference in mortality in patients who
received contrast vs. those who did not.229 This was despite the fact
that patients in the contrast group were at increased risk compared
with non-contrast group. A subsequent observational study showed
that in the contrast group, patients are 24% less likely to die com-
pared with the non-contrast group in over 4 million patients.230 This
is likely because diagnosis of life-threatening conditions is made when
contrast is used and action taken. In a latest propensity-matched
study of >16 000 patients in each group the study showed: (i) patients
undergoing echocardiography with a ultrasound contrast agent had
lower mortality at 48 h compared with patients undergoing non–con-
trast-enhanced echocardiography (1.70% vs. 2.50%), with an odds
ratio 0.66, 95% confidence interval (CI) 0.54–0.80; (ii) patients under-
going echocardiography with a contrast agent had lower hospital stay
mortality compared with patients undergoing non-contrast
echocardiography (14.85% vs. 15.66%), with an odds ratio 0.89, 95%
CI 0.84–0.96.231 A European SE study included patients receiving
OptisonVR , SonoVueVR or no contrast and found that the overall inci-
dence of adverse events was not different between the three
groups.232 Another UK study involving 4000 patients showed no dif-
ference in acute complication rate in patients who received contrast
vs. those who did not during SE, and this is despite the fact that the
patients in the contrast group were in the higher risk group.233. In a
study over 10 000 patients receiving contrast vs. similar numbers not
receiving contrast during SE were compared. No difference in serious
adverse events were noted between the two groups.234 Similarly
MCE during SE was found to be safe.143,235 A study in the USA
included 523 receiving OptisonVR and 523 receiving LuminityVR during
SE and analysed adverse cardiovascular and pulmonary effects.236.
The incidence of side effects did not differ significantly between the
two groups. Safety in patients with pulmonary disease and severe pul-
monary hypertension has been demonstrated in several studies.237–
241.These data firmly establish the use of contrast agents in severe
pulmonary artery hypertension. Side effects have been noted with
contrast agents, but they are usually mild and transient. Serious aller-
gic reactions have been observed, at a very low incidence (estimated
to be 1:10 000). Table 11 lists risk categories observed during usage
of competing investigations.242 Therefore, the evidence shows that
contrast echocardiography is very safe in clinical practice. The only
absolute contraindications for administration of contrast agents avail-
able in the market today, i.e. SonovueVR (LumasonVR in USA),
LuminityVR (DefinityVR in USA) and OptisonVR are in patients with
known or suspected intracardiac cardiac shunting of significant
degree or known hypersensitivity to the agent. The contraindications
in the former scenario have been questioned.243 Meanwhile, the FDA
has lifted the contraindication of intracardiac shunts for DefinityVR .
Intracoronary administration is also not approved and is considered
contraindicated, although it has been performed without complica-
tions in thousands of patients with hypertrophic cardiomyopathy
undergoing septal ablation. Adverse events are rare (seen in between
1 in 1000 and 1 in 10 000 patients) and usually mild (headache, nau-
sea, dizziness, taste disturbances, paraesthesia, chest discomfort and
reactions at the injection side). They are usually transient and do
require any treatment apart from reassuring the patients. Back pain
has been reported after injections of Definity and may need treat-
ment with analgesics, this is rare with other other contrast agents. All
staff in the echo laboratory should be familiar with the symptoms of
anaphylactoid reactions such as skin erythema, urticaria, rash, dysp-
noea, throat tightness, flushing and difficulty swallowing) and know
where the drugs (allergy box) are located. Allergic reactions have
been reported within 30 min. Most of the severe adverse events are
probably due to complement activation-related pseudo allergy.
However, the treatment is the same as for immunoglobulin E-medi-
ated allergic reactions. Early diagnosis and treatment can positively
affect the severity and course of the anaphylactic reaction: IV injec-
tion of antihistaminics and steroids and small dosages of epinephrine
for symptomatic hypotension can prevent the anaphylactic shock.
Recommendations
Although serious adverse events are very rare, echocardiography labo-
ratories using ultrasound contrast agents should have a policy to deal
with adverse events. The echocardiography laboratories performing
contrast echocardiography should be equipped with the appropriate
drugs to treat severe adverse events. Echocardiographers injecting
ultrasound contrast media should be trained to recognize adverse
events and to provide the adequate treatment (see Training/accredita-




The EACVI has updated the standards and processes for accredita-
tion of echocardiographic laboratories in 2014.244 Contrast agents
have to be available for LVO in SE (basic standard). Contrast-
.................................................................................................
Table 11 Incidence of Severe Anaphylaxis by
Substance Class as Defined by the International
Collaborative Study of Severe Anaphylaxis(adapted
from reference 242)
Risk Category Incidence Substance Class
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specific imaging modalities should be available (see Contrast
agents section). According to the ESC Core Curriculum for the
General Cardiologist 2013, the trainees should acquire knowledge
in contrast echocardiography, but this has not been further speci-
fied.245 Considering the growing use of ultrasound contrast agents
and availability of suitable echocardiography scanners, there is a
need for following procedures for training. There have been no
systematic studies on how many studies using contrast agents
have to be performed to provide a reliable service. Taking the
experience from other advanced echocardiographic imaging tech-
niques such as TOE, the writing group proposes the following pro-
cedures for all physicians undergoing training in transthoracic
echocardiography:
(1) Physicians should participate in a course on contrast echocardiogra-
phy to learn the performance, interpretation, pitfalls and adverse
effects in contrast echocardiography.
(2) They should have basic life support (BLS) training.
(3) They should perform and interpret at least 25 contrast echo studies
under supervision.
(4) They should maintain competency by performing at least 50 con-
trast studies per year.
The training of physicians who apply contrast agents in SE aligns to
recommendations in the Stress Echocardiography Expert Consensus
Statement of the European Association of Echocardiography.215 It is
recommended to perform at least 50 examinations with contrast
agent under the supervision of an expert reader in a high-volume lab-
oratory, and ideally with the possibility of angiographic verification,
before starting SE on a routine basis. For perfusion, SE the committee
recommends 100 examinations supervised in a high-volume centre.
For demonstration of maintenance of competence at least 50 stress
echo examinations per year should be performed. The trainees
should also attend a course on contrast SE.
An important topic for training is to assess the adequacy of
image quality of contrast echocardiograms. The trainees should
become familiar with the criteria of an adequate contrast
echocardiogram as well of pitfalls and artefacts. In principle, the
same rules apply for studies that are performed for LVO and
those performed to assess myocardial perfusion, which is usually
assessed in addition to LV wall motion. In apical views, the focus
is usually set at the mitral valve level. The contrast in the LV
should be visible in the entire cavity with no or minimal swirling in
the near field and no attenuation in the far field (see Figure 2).246
Myocardial opacification is usually less intensive than LVO and
should not obscure the delineation of the endocardial border
(see Figure 8). The basal anterior and lateral myocardial segments
may be attenuated specially during myocardial perfusion. A trou-
bleshooting guide for suboptimal images has been developed to
optimize contrast images before recording (Table 12).
Perspectives/expectations
3D technology plays only a minor role in the current recommen-
dations for contrast echocardiography. However, we expect fur-
ther hardware and software development in the future that will
allow to investigate more patients using 3D technology.
Ultrasound agents have been used for quantitative analysis of
intraventricular flow dynamics and assessment of LV vortex,
which may provide new parameters to assess heart failure
patients.247 New ultrasound contrast agents are being developed
for molecular imaging—e.g. to detect expression of myocardial
cell membrane receptors in myocardial ischaemia.248 Recently,
therapeutic applications of ultrasound contrast media are being
investigated.249 A recent study demonstrated the ability of diag-
nostic ultrasound impulses to restore microvascular flow in
patients with ST-elevation myocardial infarction.250 These new
diagnostic and therapeutic applications utilize MCE. The latter
developments in therapeutics will encourage the manufacturers
to further improve the assessment of myocardial perfusion.
Protocols for contrast
echocardiography
Check lists can be helpful for quality control in the echocardiography
laboratory. Table 13 shows the steps to perform contrast echocar-
diography. The protocols in Perspectives/expectations section pro-
vide the details of contrast dosages and image settings for the
different indications.
The following protocols have been found to be useful in clinical
practice. They were selected, because they represent the basic
requirements and limit the amount of ultrasound contrast which is
given. Laboratories may use modifications including additional steps
or recordings in particular for the protocols in SE based on local
experience and preferences.
Rest 2D echocardiography
LV volumes and EF, regional wall motion
Use intermediate MI or low MI contrast imaging mode (see Table 2) if
both modalities are available first choice should be low MI technique;
use the presets of the manufacturers, which work in most patients
(Figure 2).
Table 12 Troubleshooting for contrast recordings
obtained in apical views: the echocardiographer assesses
the opacification in the apical third and basal third of
the LV cavity for swirling and attenuation
Problem To do
• Apical swirling good basal
contrast
Reduce MI
• Basal attenuation no apical
swirling
Increase MI (contrast infusion)
wait longer after bolus
injection
• Apical blooming and basal
attenuation
Reduce infusion rate of contrast
wait longer after bolus
injection
• Apical swirling and inhomogene-
ous contrast in the entire cavity
Increase infusion rate of contrast
or higher volume of the bolus
This guide is also useful in MCE. A homogeneous LV opacification of the LV cavity
without attenuation or swirling is the prerequisite for adequate display of con-
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– bolus injection of 0.5 mL SonoVueVR /0.2–0.3 mL OptisonVR , 0.1
mL LuminityVR or SonoVueVR infusion 0.7–1.2 mL/min;
– acquire apical four- and two-chamber views;
– start acquisition not before 20 s after contrast injection;
– adjust MI/gain/focus to ensure good endocardial definition in
all segments;
– inject additional contrast or increase infusion rate, if insuffi-
cient contrast and
– use biplane Simpson method as for non-contrast
echocardiography.
3D echocardiography (limited experience) (Figure 3):
• same procedure but usually higher dosage of contrast needed;
• infusion of the contrast agent facilitates adjustment of machine
settings;
• the semi-automated analysis software for LV analysis cannot be
used and
• use biplane Simpson method on reconstructed, unforshortened
views.
Myocardial perfusion
Myocardial perfusion needs low MI contrast imaging mode (see
Table 2), use the presets of the manufacturers:
– infusion of the contrast agent recommended, SonoVueVR 0.7–
1.5 mL/min, LuminityVR 1.3 mL vial diluted in 30 mL saline, start
with 1 mL/min;
– acquire flash-replenishment sequences (15 cardiac cycles) of
the apical 4-, 2- and 3-chamber views with the flash delivered
after the second cardiac cycle (Figure 8)
The cardiac cycles following the flash show very good endocardial
definition and can be used to measure LV volumes and ejection frac-
tion (see rest 2D echocardiography).
Doppler echocardiography
Doppler echocardiography use same PW- or continuous-wave
Doppler settings as for non-contrast studies:
– no extra contrast injection needed, when performed after
recordings for assessment of LV volumes and EF (section
8.1.1), the small amounts of contrast agent still present during
washout after image acquisition for LV volumes or perfusion
are enough
– reduce emission power (MI) until Doppler spectrum shows
regular grey levels
TOE for assessment of LAA
Use harmonic imaging or contrast-specific modality, which are avail-
able in some TOE scanners, reduce MI to <0.3, reduce penetration
depth and/or use Zoom mode.
– same dosages as for TTE (rest 2D echocardiography);
– can take >30 s to opacify the LAA;
– record in at least 2 imaging planes and
– flash replenishment sometimes helpful to assess flow into
LAA.
For all SE methods, low MI contrast imaging modalities are recom-
mended (Table 2). Usually, the presets provided by the manufacturers
are applicable in most patients.
Exercise SE
Supine bicycle
Table 13 Checklist for contrast echocardiography
(1) Check indication
(2) Assess patient for contraindications of contrast agents
(3) Inform patients about the risk/benefit and obtain consent
(4) Insert IV (right arm preferable) or check available IV access
– central lines may be used
– in SE both the contrast agent and pharmacologic stress agent
(eg dobutamine or adenosine) can be administered via a
three-way tap through the same IV
(5) Prepare contrast agent
– follow instructions of the manufacturer for preparation
– avoid negative pressure when transferring the contrast agent
from the vial into the syringe
(6) Check whether the adequate contrast setting is active on the
echocardiography scanner (see Contrast imaging modalities sec-
tion), this depends on the indication
(7) Slow bolus injection (see Contrast administration section) infu-
sion should be considered for SE
(8) Check whether images are adequate
if necessary optimize images before recording (see Table 12)
(9) Ask and observe the patient for possible adverse events
(10) Document the indication for contrast use and the total contrast
dosage which was administered in the echo report
Rest – contrast bolus injection or infusion like in rest
2D echocardiography (see LV volumes and EF,
regional wall motion);
– acquire apical four, two and three chamber
and parasternal short axis views;
– start acquisition not before 20 s after contrast
injection and
– when infusion is used, pause infusion after
image acquisition.
25 Watts – bolus injection or infusion (same dosage as at
rest);
– acquire apical four, two and three chamber
and parasternal short axis views and
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Optional: Assessment of myocardial perfusion in addition to LV
wall motion, see Myocardial perfusion section
The flash-replenishment sequences can be performed at rest and
in the early recovery period (should complete by 90 s after cessation
of exercise), when the patient can hold the breath. The stress
echo protocols on most ultrasound scanners allow acquisition of the
flash-replenishment sequences in addition to the standard loops for
assessment of wall motion by pausing the regular stress protocol
(Figure 12).
Treadmill
*For additional perfusion imaging (optional), see Myocardial perfu-
sion and Supine bicycle sections
Dobutamine stress echocardiography
Assessment of myocardial ischaemia
For assessment of myocardial perfusion in addition to LV wall
motion, see Myocardial perfusion section.
The flash-replenishment sequences can be performed in
addition or instead of to the single beat recordings performed in
the early recovery period in most stress imaging protocols. The
stress echo protocols on most ultrasound scanners allow acquisi-
tion of the flash-replenishment sequences in addition to the
standard loops for assessment of wall motion by pausing the reg-
ular stress protocol (Figure 13).
Assessment of myocardial viability
Peak stress – bolus injection or infusion (same dosage as at
rest);
– acquire apical four, two and three chamber
and parasternal short axis views and
– when infusion is used, continue infusion until
recovery.
Recovery – bolus injection or continue infusion (same dos-
age as at rest) and
– acquire apical four, two and three chamber
and parasternal short axis views.
Rest – patient on the imaging bed;
– bolus injection of contrast or infusion like in
rest 2D echocardiography (LV volumes and
EF, regional wall motion section);
– acquire apical four, two and three chamber*
and parasternal short axis views and
– then patient is moved to the treadmill.
Stress – repeat bolus injection or restart infusion when
patient is exercising at;
– maximum effort or usual criteria for termina-
tion of exercise;
– move the patient to the imaging bed;
– start acquisition immediately as soon as possi-
ble and acquire same views and as during rest.
Rest – contrast bolus injection or infusion like in rest
2D echocardiography (LV volumes and EF,
regional wall motion section)
– acquire apical four, three and two chamber
and parasternal short-axis views;
– start acquisition not before 20 seconds after
contrast injection and




– bolus injection or infusion (same dosage as at
rest);
– acquire apical four, two and three chamber
and parasternal short-axis views and
– when infusion is used, pause infusion after
image acquisition.
Peak stress – bolus injection or infusion (same dosage as at
rest);
– acquire apical four, two and three chamber
and parasternal short-axis views and
– when infusion is used, continue infusion until
recovery.
Recovery – bolus injection or continue infusion (same dos-
age as at rest) and
– acquire apical four, two and three chamber
and parasternal short-axis views.
Rest – contrast bolus injection or infusion like in rest
2D echocardiography (LV volumes and EF,
regional wall motion section);
– acquire apical four, two and three chamber and
parasternal short-axis views;
– start acquisition not before 20 s after contrast
injection and




– bolus injection or infusion (same dosage as at rest);
– acquire apical four, two and three chamber and
parasternal short-axis views and




– bolus injection or infusion (same dosage as at
rest);
– acquire apical four, two and three chamber and
parasternal short-axis views and




– bolus injection or infusion (same dosage as at rest);
– acquire apical four, two and three chamber and
parasternal short-axis views;
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..For assessment of myocardial perfusion in addition to LV wall
motion, see Assessment of myocardial ischaemia section.
Homogeneous myocardial contrast enhancement at rest suggests
viability. However, demonstrating contractile reserve and/or biphasic
response with dobutamine stress are further supporting findings for
viability (Figure 14).
Vasodilator SE using contrast agents
Dipyridamole SE—high dose
Measurement of LAD flow using PW Doppler at rest and during
dipyridamole infusion (6 min) is recommended (Figure 15A).
For assessment of myocardial perfusion in addition to LV wall
motion, see Myocardial perfusion section.
Figure 12 Protocol for supine bicycle stress and using contrast
agent (CA) infusion or injections. In this example, the patient was able
to exercise at 100 W. The load is increased by 25 W every 3min.
Cessation of exercise according to the EAE consensus for stress echo-
cardiography.217 In this example, the patient exercised at maximum
effort at 100 W. Additional images may also be acquired at intermedi-
ate stress (70% of target heart rate). 4CV,four-chamber view; 2CV,
two-chamber view; 3CV, three- chamber view (parasternal long axis
view can be used instead); SAX, parasternal short axis view.
Figure 13 Protocol for dobutamine stress/assessment of ischae-
mia and using contrast agent (CA) infusion or injections. In this
example, the dobutamine infusion had to be increased up to 40lg/
kg/min and atropine was injected to reach target heart rate. To min-
imize the time of the examination, atropine can be started already
at the 30lg/kg/min stage when the heart rate has not increased by
at least 20% from baseline. Cessation of exercise according to the
EAE consensus for stress echocardiography.217 For abbreviations,
see Figure 10. Additional recordings may also be acquired at inter-
mediate stress (70% of target heart rate).
rest - Contrast bolus injection or infusion
like in rest 2D echocardiography
(LV volumes and EF, regional wall
motion)
- Acquire apical four, two and three
chamber and parasternal short-axis
views
- Start acquisition not before 20 s
after contrast injection
- When infusion is used, pause infu-
sion after image acquisition
0.84 mg/kg Dipyridamole
infusion in 6 min
3 minutes after start of
Dipyridamole infusion
- Acquire apical four, two and three
chamber and parasternal short-axis
views
- Start acquisition not before 20 s
after contrast injection
- When infusion is used, pause infu-
sion after image acquisition
6 minutes after start of
Dipyridamole infusion
- Contrast bolus injection or infusion
(same dosages as at rest)
- Acquire apical four, two and three
chamber and parasternal short-axis
views
- When infusion is used, pause infu-
sion after image acquisition
10 minutes after start of
Dipyridamole infusion
- Contrast bolus injection or infusion
(same dosages as at rest)
- Acquire apical four, two and three
chamber and parasternal short-axis
views
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*The contrast infusion may be paused, when systems with sensitive
coronary Doppler are used.
**Increase adenosine dosage by 20 mg/kg/min (up to 220 mg/kg/
min) when the patients show no signs of an adenosine effect such as
flushing, change in heart rate, increase in LAD velocity and angina or
worsening LV wall motion (Figure 16).
Rest - Infusion of contrast agent recom-
mended (see section Myocardial
perfusion)
- Acquire apical four, two and three
chamber views
- Start acquisition not before 20 s
after contrast injection
- Record LAD flow using PW-
Doppler (RCA, LCX if possible)
Adenosine infusion 140mg/kg/min)
for maximum 6 minutes
1 minute after start of
Adenosine infusion
- Record LAD flow using PW-
Doppler (RCA, LCX if possible)*
- Adjust adenosine infusion if
needed**
- Acquire apical four, two and three
chamber views as flash-replenish-
ment sequences (see figure 16)
Recovery - Acquire apical four, two and three
chamber views as flash-replenish-
ment sequences
Figure 14 Protocol for low-dose dobutamine stress/assessment
of viability and using contrast agent (CA) infusion or injections. For
abbreviations, see Figure 10. When there is no improvement in con-
tractility in the akinetic segments up to 20lg/kg/min, the test can be
terminated. High-dose dobutamine infusion may be added to demon-
strate a biphasic response (see dobutamine protocol for assessment
of myocardial ischaemia, Figure 10) in those patients who show
improvement in contractility of akinetic segments or when there is a
suspicion of ischaemia in other segments with preserved contractility
at rest. Perfusion assessment in dobutamine non-responsive segments
improves sensitivity for the detection of myocardial viability.
Figure 15 Protocol of state-of-the-art high-dose dypyridamole
SE suggested by the EAE215. In addition to 2D echocardiographic
recordings measurement of the blood flow in the LAD is recom-
mended at rest and at the end of the dipyridamole infusion. (B)
Protocol for low-dose dypyridamole SE, which is suitable assess-










































Rest – infusion of contrast (SonoVue 0.7–
1.2 mL/min) recommended;




before 20 s after contrast injection and
– pause infusion after image
acquisition.
Over 4 min Dipyridamole infusion 0.56 mg/kg
2 min after the end
of Dipyridamole
infusion
– start infusion of contrast agent
(same dosage as at rest) and
– acquire apical four, two and three
chambers as flash-replenishment
sequences (Figure 15B).
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